Brought to you by 
Dementia drug developer Axovant nets $337mm in record-breaking IPO
05 Jan 2021
Executive Summary
Axovant Sciences Ltd. (dementia therapeutics) netted $337mm in its initial public offering of 24.2mm shares (including the overallotment) for $15. Affiliates of Visium Asset Management and RA Capital Management agreed to buy 10mm shares. The company had set terms of 17.9mm shares at $13-15. This marks the fourth-largest US biotech IPO ever, coming in behind Genentech ($1.9bn), Catalent Pharma ($952mm), and Talecris (now part of Grifols; $550mm).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dementia drug developer Axovant nets $337mm in record-breaking IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice